Quantcast
Last updated on April 17, 2014 at 11:32 EDT

Latest Opioids Stories

2012-09-13 02:28:28

SAN FRANCISCO, Sept. 13, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2012 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Wednesday, September 19, 2012 at 10:30 a.m. Eastern time. The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This...

2012-09-12 02:29:12

AACHEN, Germany, September 12, 2012 /PRNewswire/ -- In the first half of 2012 Gruenenthal Group, an international pain therapy expert, reached revenues of EUR473 mn (vs. EUR 483 mn in H1 2011). Corrected by divested businesses, core business grew by 9 per cent in the first half of 2012. Growth was driven by the continued success of Gruenenthal's global pain brands, in particular the strategic growth drivers Palexia(R) (+EUR19 mn) and Versatis(R) (+EUR16 mn) in Europe and...

2012-08-27 10:25:25

MENLO PARK, Calif., Aug. 27, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology. Under the terms of the agreement Janssen received a non-exclusive license and other rights to certain Acuform patents. In exchange, Depomed will receive an upfront payment of $10 million and will receive a low single digit royalty on net sales of NUCYNTA® ER...

2012-08-23 02:25:48

REDWOOD CITY, Calif., Aug. 23, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced dosing of the first patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia (PCA) system. This third ARX-01 Phase 3 study is a...

2012-08-21 02:26:59

SAN DIEGO, Aug. 21, 2012 /PRNewswire/ -- Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain, announced today that it has initiated a first-of-its-kind, large-scale prospective clinical outcomes study of its pharmacogenetic test. The study, which will encompass more than 30 practice sites nationally, is designed to evaluate the relationship between CYP genotype, as determined by Millennium...

2012-08-20 02:29:16

RALEIGH, N.C., Aug. 20, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that enrollment and the clinical portion of the pivotal pharmacokinetic study for BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence has been completed. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) As agreed with the U.S. Food and Drug Administration (FDA) in February 2012, the study, referred to as BNX-103, was designed to compare the...

2012-08-17 02:21:43

GLENVIEW, Ill., Aug. 17, 2012 /PRNewswire-USNewswire/ -- The American Academy of Pain Medicine (AAPM) responded Wednesday to the petition submitted to the Federal Drug Administration (FDA) by Physicians for Responsible Opioid Prescribing (PROP) requesting label and dosing changes in connection with certain opioid products. In its comments to the FDA, the AAPM said it shares the commitment of the petitioners to find ways to curb prescription pain medication harm. In its response, which was...

2012-08-17 06:08:59

Overdose has surpassed car accidents as leading cause of death in Rhode Island, Connecticut A Rhode Island Hospital researcher has found that the use of electronic prescription drug monitoring programs (PMPs) may have a significant impact on the demand for drug treatment programs and how prescribers detect and respond to abuse of painkillers. The study by Traci C. Green, Ph.D., MSc, research scientist in Rhode Island Hospital's department of general internal medicine, is published online...

Serious Illness And Death Found In Children Who Were Given Codeine
2012-08-16 13:12:11

Connie K. Ho for redOrbit.com — Your Universe Online The Food and Drug Administration (FDA) recently stated that a few children who were given codeine, a pain reliever, after surgery may have developed serious breathing problems that lead to death. The FDA first learned about the issue from perusing articles in the New England Journal of Medicine in 2009 as well as the journal Pediatrics in 2012. According to My Health News Daily, the FDA stated that it would begin reviewing...

Heroin And Morphine Addiction Can Now Be Blocked
2012-08-16 07:17:36

Clinical trials possible within 18 months In a major breakthrough, an international team of scientists has proven that addiction to morphine and heroin can be blocked, while at the same time increasing pain relief. The team from the University of Adelaide and University of Colorado has discovered the key mechanism in the body's immune system that amplifies addiction to opioid drugs. Laboratory studies have shown that the drug (+)-naloxone (pronounced: PLUS nal-OX-own) will...